Hess Midstream Partners LP (HESM) signals a pivotal shift towards robust free cash flow generation, forecasting a 40% drop in capital expenditures for 2026 as its core system build-out concludes. Despite near-term weather headwinds, strong minimum volume commitments underpin financial targets through 2028.
Fifth Third Bancorp has finalized its acquisition of Comerica in under four months, a swift consolidation that underscores a new era of accelerated bank mergers driven by regulatory shifts and the relentless pursuit of scale.
A new cache of Jeffrey Epstein's emails has implicated former Prince Andrew, his ex-wife Sarah Ferguson, and senior Labour figure Peter Mandelson, revealing intimate correspondence, financial dealings, and raising fresh questions about influence and accountability at the highest levels of British society.
Turkish energy firm Reges Elektrik has completed its acquisition of Tuşpa Enerji, unlocking the start of operations at the 70MW Demirli Wind Power Project in Kırşehir and marking its strategic shift into large-scale power generation.
The grocery sector begins 2026 with significant executive turnover, including leadership changes at Lidl US, The Save Mart Companies, and a major realignment within Walmart's top ranks ahead of its CEO transition.
Apple's acquisition of Israeli AI audio startup Q.ai signals a deeper push into biometric wearables, as the tech giant reportedly reshuffles its 2026 roadmap to prioritize premium iPhones—including a long-rumored foldable model—while navigating ongoing component shortages.
The all-stock deal creates one of the nation's largest independent oil and gas producers, headquartered in Houston, with combined assets poised to reshape the competitive landscape of the shale sector.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Congress faces a critical vote to avert a prolonged shutdown, while newly released documents shed light on the Minneapolis shooting involving immigration officers and the Epstein case continues to reverberate.
A highly sensitive whistleblower complaint alleging misconduct by Director of National Intelligence Tulsi Gabbard has been locked within the intelligence bureaucracy since May, with Congress aware of its existence but blocked from reviewing it amid accusations of obstruction.
H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.
Canadian junior miner G2 Goldfields Inc. (TSX: GTWO), despite recent losses, is projected by analysts to reach profitability within two years, backed by aggressive growth forecasts and a debt-free balance sheet.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.
